{"name":"RedHill Biopharma","slug":"redhill","ticker":"RDHL","exchange":"NASDAQ","domain":"redhillbio.com","description":"RedHill Biopharma is a specialty pharmaceutical company focused on gastroenterology and other therapeutic areas. The company has a portfolio of products, including Aemcolo, Talicia, and Bekinda. RedHill Biopharma is a relatively small player in the gastroenterology market, but its products have shown promise in treating various gastrointestinal disorders.","hq":"Tel Aviv, Israel","founded":2006,"employees":"~75","ceo":"Dror Ben-Asher","sector":"Gastroenterology / Specialty Pharma","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"1.3B","metrics":{"revenue":95000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Aemcolo patent cliff ($10.0M at risk)","drug":"Aemcolo","type":"patent_expiry","sentiment":"negative"},{"date":"2031-06-01","label":"Talicia patent cliff ($5.0M at risk)","drug":"Talicia","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"RHB-102","genericName":"RHB-102","slug":"rhb-102","indication":"Nausea and vomiting associated with chemotherapy","status":"phase_3"},{"name":"Opaganib","genericName":"Opaganib","slug":"opaganib","indication":"Other","status":"discontinued"},{"name":"BEKINDA","genericName":"BEKINDA","slug":"bekinda","indication":"Prevention of nausea and vomiting associated with chemotherapy and radiation therapy","status":"phase_2"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"RHB-105","genericName":"RHB-105","slug":"rhb-105","indication":"Treatment of COVID-19","status":"phase_3"},{"name":"Rifamycin SV MMX","genericName":"Rifamycin SV MMX","slug":"rifamycin-sv-mmx","indication":"Clostridioides difficile infection (CDI)","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"RHB-104","genericName":"RHB-104","slug":"rhb-104","indication":"Crohn's disease (moderate to severe, MAP-positive or MAP-negative)","status":"phase_3"}]}],"pipeline":[{"name":"RHB-102","genericName":"RHB-102","slug":"rhb-102","phase":"phase_3","mechanism":"RHB-102 is a gastric motility agent.","indications":["Nausea and vomiting associated with chemotherapy"],"catalyst":""},{"name":"Opaganib","genericName":"Opaganib","slug":"opaganib","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BEKINDA","genericName":"BEKINDA","slug":"bekinda","phase":"phase_2","mechanism":"Bekinda is a delayed-release tablet formulation of ondansetron, a serotonin 5-HT3 receptor antagonist.","indications":["Prevention of nausea and vomiting associated with chemotherapy and radiation therapy"],"catalyst":""},{"name":"RHB-104","genericName":"RHB-104","slug":"rhb-104","phase":"phase_3","mechanism":"RHB-104 is a combination of three antibiotics (clarithromycin, rifabutin, and clofazimine) designed to target Mycobacterium avium subspecies paratuberculosis (MAP) in Crohn's disease.","indications":["Crohn's disease (moderate to severe, MAP-positive or MAP-negative)"],"catalyst":""},{"name":"RHB-105","genericName":"RHB-105","slug":"rhb-105","phase":"phase_3","mechanism":"RHB-105 is a combination of rifabutin and hyoscyamine for the treatment of COVID-19.","indications":["Treatment of COVID-19"],"catalyst":""},{"name":"Rifamycin SV MMX","genericName":"Rifamycin SV MMX","slug":"rifamycin-sv-mmx","phase":"phase_3","mechanism":"Rifamycin SV MMX is a modified-release antibiotic that targets bacterial RNA polymerase to inhibit bacterial protein synthesis, with enhanced delivery to the colon.","indications":["Clostridioides difficile infection (CDI)","Traveler's diarrhea"],"catalyst":""}],"recentEvents":[{"date":"2023-02-28","type":"earnings","headline":"RedHill Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results","summary":"RedHill Biopharma reported its financial results for the fourth quarter and full year 2022, with revenue of $13.4 million and a net loss of $24.5 million.","drugName":"","sentiment":"neutral"},{"date":"2022-06-01","type":"deal","headline":"RedHill Biopharma Announces Agreement with Gilead Sciences to Develop and Commercialize RHB-107","summary":"RedHill Biopharma announced an agreement with Gilead Sciences to develop and commercialize RHB-107, a treatment for COVID-19.","drugName":"","sentiment":"positive"},{"date":"2021-11-10","type":"regulatory","headline":"FDA Approves Aemcolo for the Treatment of Traveler's Diarrhea","summary":"The FDA approved Aemcolo, a treatment for traveler's diarrhea, marking a significant milestone for RedHill Biopharma.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBqQTFObTlSZFpvTDJSaWlIeXhuSnVWbEY3bER6NnNqMlZjaEQ2OUdLSDJEQ29lc1cyUjZSLS00aGlvdDJsZFV2TlFuR2ZHRUhxa1poV2NKTWpac1VETTNr?oc=5","date":"2026-04-02","type":"pipeline","source":"ChartMill","summary":"RDHL Stock Price, Quote & Chart | REDHILL BIOPHARMA LTD-SP ADR (NASDAQ:RDHL) - ChartMill","headline":"RDHL Stock Price, Quote & Chart | REDHILL BIOPHARMA LTD-SP ADR (NASDAQ:RDHL)","sentiment":"neutral"},{"date":"2026-03-05","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-02-25","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-01-27","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-01-22","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-01-05","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: 6-K","headline":"6-K Filing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxPcy1Oa25uZGRxd2JJNlRDaTllbnlZdUYyTjBPWXpRV01ETmVLbzJaM2QybWhDeWhtdDcwaC0xZTlqSmx0ZFZwZ1Fhbk0yM0p3aHVRSTVaWHFZM2RZU0MzRFBVaHc2V2E4ck5HY1lLX0R3aGNIbjZSLXNFVDB4NmN0TUlNbndIZUdOTkJWQ1JCX3RvVWttWVNHZ292RGxRclRvTjFrb3ZodHMxOFBYX29KdU5sdWpHcXhKbHJpZzhWTkkybmZLclh1eUF1Z3lBV1c5OUlVbGdYdGZkT2FBa3Bmc3l3NA?oc=5","date":"2025-12-01","type":"pipeline","source":"PR Newswire","summary":"RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement - PR Newswire","headline":"RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxQT3MwbmVpZVJ6LWh1VmhtdVRuQmNkVkVkWlRROGlKbmhGNVRtT2dOMk9TdlFWVVktTVplYmtkdVE5UGEtN2ZJYWhmcktSdktyQzJaUDNKUWRpSkUxWEFkM0E5bzFqM3paWW1JYjNsLTFsM2RlWFJCTllHdTBTWlZNN1RLSml5ZXE3eUVxTXgxNFNabkNDeWE2dk0yWmFBLU1MNGIzRVhoVzE1TW1IS2tYODlfV2E0b2wtamt2YW1xT1VxQllHUHdGbkVOcGlFY3U5MW9Ja3JNMmdhUTBRVUdXbHl5Sk83VHFKbkZCSg?oc=5","date":"2025-10-20","type":"deal","source":"PR Newswire","summary":"RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal - PR Newswire","headline":"RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxNbFBHN2c0SDREWFg2YVBNZ3ZrUHc3aHVrUVpfVWRrMUk2VzF3YmhLQmRDM0JOWTR5MlAtcHMtNG5jSzFvRmJuRTJ5RGZMOHU3TjRNYTRscmwwQ0Y2elJkZmI4ZVJkU2VSVmVyTXJSendnYjJtOU15UlRhMGR5UENSNkVLdGtFdnJxcUtweThRNXY0YldWdEZ5NzJ6OGcwM1BWRTZ1MmFZWUYxeGJOV3hEcEswM09WTTBsb091b01PNlkydnFvOXR0YVVUY0xtZ3BLNzZtLVV1dTlMLW5XdHc?oc=5","date":"2025-10-06","type":"deal","source":"PR Newswire","summary":"RedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia® - PR Newswire","headline":"RedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia®","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxPY0ZaZ0g2YXlXY3dPMVJYWlBtdlQ2enNBYWtLaWZrTEc2WUF1YjFIbHRtNDJfN1pjSG5nU18tMlRmeTlMWW5zNFFuZnRGc2VsdXBvTGY3R0Jsc25mVnNRT3I0ZktIdDNidkctVEcwY1ZBc1BkYlFlYnJEa0FzMklocFlzWU5NNHByOGl0eGdZVDhuNUpSTlRHdC1iQTlpZmV2VlNaNTFsc0JQckxvU2MtYXBhQ0hEbm9pS3pCdkExU2Y3VWRQQ0ltOWM5TWc2YVBQMUJOWWE5ektXSmJNR2wyU3RKNzUzUQ?oc=5","date":"2025-04-17","type":"pipeline","source":"PR Newswire","summary":"RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency - PR Newswire","headline":"RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwJBVV95cUxPek9yNzJxZThqOXpQS3RUNGh0X25kemphQVJRZlNxbWwzLVdEbnkxYi15SGtWdk1vYUcyWWEtdG5PWHlkUXN5b1ZGUGhpM1RidWpTbHJWRVJvZHN6ZFJrTkd1LVc0T1Fyb1hKbjY1QXR4TThiUkxSc3J0Y3k3ZWQzRTh0ZnkwN2VFX2JNZ0pBeldBbEl0U3NVaG1mMUtGdWZZeVh5cUV0NjZNTTRUNVpXY3RDNlhLbFdHeXFMeTltYUwyNUpUNlVZZ1NRbFVMYlVzNF80QklMSi1VcHIxZnVqbHBOa2ZRTXhSMlkxTVl5eWZNTlZHV2RoQ2p5LUdkbENGbFc1Zlo0b3JTOXdDTkFQQmxUMW45Z29FMFRsWHJDekVOTWp5NjdtLXE3cjZPSXRKZnZSTkxKYjhwU2M?oc=5","date":"2025-02-25","type":"deal","source":"PR Newswire","summary":"RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties - PR Newswire","headline":"RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Pot","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPLUZNdm9zS012dVg5YjBXamtLdXoxVllQcWVvLVpyTjFsZmNoc3k2dzdGeklDd1B1WGxtb1hSNFF3ckdaQldMSDN1VGhZLXV4S0lGNHF3ZzNkYkhjNWFlNnFVMk8tODUyWDBvaDFiNC1OYkZpd2VLbGI1WVR4d292Sy0zN2Z6LWpBYmlkbGdodkgyMkVmeEVHakx1SF9KZTRlQzVZS0dB?oc=5","date":"2024-07-25","type":"pipeline","source":"The Business Journals","summary":"Raleigh pharma gets cash jolt at critical time - The Business Journals","headline":"Raleigh pharma gets cash jolt at critical time","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxOMzI4MXFXYy1YLVJCWC1ZYTFBR3Y4NTB4MTVVanlYWjRMcEhoNndacHhacUtINkgyR3BjUTlfcGZnV3ktTGpoQ2JzLUtaOS1ER240cVNzRExUWU5KWjlpNTFlQUlZWjhRUHAtMjNnWjkxODFzNFhMYk1sOXZqTTJsUTVrRDlIakhxRWdfUmtsaUZ2ZDF3S09FaHhnZFFRRU0xY29aZGJEcmtSOThtUEFhYkRsdnZVSDA2cEFEQ0twZEZveGxWU2djY0ZCdXpwNWFHR01wOVJDZnF5Y3pLZEFv?oc=5","date":"2024-07-22","type":"pipeline","source":"PR Newswire","summary":"RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia® Lien - PR Newswire","headline":"RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia® Lien","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxONy1IaU1VVjgyU3dwTzVuZEI1QU5NMzZxeEI1YXY2SHpkYzRRcGZRUGlmdXg4S2ZCNVMzcWs0Qjg0cEo2ZEZBd1dETDUwM1VSYllSNkVCYzBCd3l6b05ld0ZiQXJTbDdkcWdvUXUwa1dxZW5RVjV2MDBvUjZ3ck5PdEZUYmFUSDJoYWFwYWZCMDJTWlVuYmotV2FQOHp5bWwtVFlPMnFiWDJtcXd1REs4VFNzSG5adWc3b1FzVXhib2RqOWFHN2daOGZqZmp2bl9kOG9SWE45MnV0U1Z6VTFLMlFBdWs5dkdQa0pJcTFkeGhKSEpGNWJSemxUbVI1UQ?oc=5","date":"2021-01-11","type":"trial","source":"PR Newswire","summary":"RedHill's Partner Cosmo Pharmaceuticals Successfully Completes Phase 2 Study of Rifamycin SV-MMX 600mg in IBS-D - PR Newswire","headline":"RedHill's Partner Cosmo Pharmaceuticals Successfully Completes Phase 2 Study of Rifamycin SV-MMX 600mg in IBS-D","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE5QOGctMGxneEZxZzhlblctX0ZoUlN2UlJwazE4cVBhc2R0T0liUFpRWkYxRll2UzBkMHBRdC04bXFQZHd0TXFFMGh0RFFiaVVjb095Mnc3MGExb1Z0?oc=5","date":"2017-07-21","type":"pipeline","source":"TradingView","summary":"RDHL Stock Price and Chart — NASDAQ:RDHL - TradingView","headline":"RDHL Stock Price and Chart — NASDAQ:RDHL","sentiment":"neutral"}],"patents":[{"drugName":"Aemcolo","drugSlug":"rifaximin","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":10000000},{"drugName":"Talicia","drugSlug":"gavacovir","patentNumber":"","type":"Patent Cliff","expiryDate":"2031-06-01","territory":"US","annualRevenue":5000000}],"drugCount":6,"phaseCounts":{"phase_3":4,"discontinued":1,"phase_2":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Allergan","Gilead Sciences","Janssen Pharmaceuticals"],"therapeuticFocus":["Gastroenterology","Infectious Diseases"],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":null,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":null,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}